MEDIMMUNE LIMITED

Their core work

MedImmune is the biologics research and development arm of AstraZeneca, focused on developing antibody-based therapeutics and biopharmaceutical products. Within H2020, they serve as an industry training host in Marie Skłodowska-Curie networks, providing early-stage researchers with hands-on experience in protein engineering, immunology, and bioprocess development. Their contributions span from protein formulation and directed evolution to quantitative immunology and continuous biomanufacturing. As a large pharma R&D operation based in Cambridge, they bring deep expertise in translating biological research into drug development pipelines.

What they specialise in

How they've shifted over time

MedImmune's early H2020 participation (2016-2017) centered on wet-lab biology — protein formulation, directed evolution, nucleic acid tools, and disease-focused immunology including multiple sclerosis biomarkers and immunophenotyping. By 2018-2019, their involvement shifted toward computational and process-oriented work: quantitative immunology modelling, biostatistics, and continuous biomanufacturing with regulatory considerations. This reflects a broader pharma industry trend of integrating data science into biologics R&D while also investing in manufacturing innovation.

MedImmune is moving from purely discovery-oriented research toward digitalized, process-efficient biologics development — future partners should expect interest in computational modelling, continuous manufacturing, and regulatory science.

How they like to work

MedImmune exclusively participates as a non-coordinating partner, consistent with large pharma companies that join EU training networks to host researchers rather than lead academic consortia. With 87 unique partners across 19 countries from just 6 projects, they operate in large, diverse consortia — typically MSCA training networks with 10-15 partners each. This makes them an accessible industry partner: they are experienced at working within multi-partner academic-industrial frameworks and provide real-world R&D environments for trainees.

MedImmune has collaborated with 87 unique partners across 19 countries through predominantly MSCA training networks, giving them one of the broader partner networks relative to their project count. Their reach spans most of Western and Northern Europe with strong academic connections.

What sets them apart

As AstraZeneca's dedicated biologics R&D unit, MedImmune offers something most industry partners in MSCA networks cannot: direct access to a full-scale pharmaceutical drug development pipeline. Their Cambridge campus bridges academic research and industrial application, making them an ideal host for translational training. For consortium builders, they bring credibility, industry-grade infrastructure, and a track record of integrating into academic-led networks without dominating them.

Highlights from their portfolio

• PIPPI
  Largest single EC contribution (EUR 546,576) — a training network on protein formulation, directly relevant to MedImmune's core biologics business.
• QuanTII
  Represents MedImmune's shift toward computational immunology, combining mathematical modelling with T cell immunotherapy — a high-growth area in pharma.
• CODOBIO
  Their only third-party role, focused on continuous biomanufacturing and regulatory science — signals strategic interest in next-generation production processes.